Check
@tradingformils latest article, I liked it. Went into a lot of depth. Any further questions from there then post here.
From you asking about rev/profit expectations I will oblige, but I can also clearly tell that you are not acknowledging my point about our peers.
None of our immediate MedCann peers make profit, in fact some dont make any revenue at all.
IHL has the best revs compared to immediate peers, even those like AGH (200M+) and BOT (200M+), albeit BOT strength is not in revenue but in its clinical trials and IP. Also decreasing cash burn every qtr, increasing sales from dental biz plus -800K/qtr on costs underway. Find me another AU MedCann that has better cost burn.
Yet, IHL hasnt even started selling Oils through CVL yet, when they do and according to Dr Sud calc we should be literally doubling AGH revenue when you combine total rev with our dental biz. Yet they are valued so much more, headscratcher really. (For now)
Now lets do BOT. BOT has cash, and lots of it thanks to recent raises but burns huge amounts of cash and has no rev. Benefits? Trials and IP. Do we have that? 4 coming, within the quarter. Do we have cash? Yes, 1.7M now but 20M+ from options that expire in 2020. Costs? Limited to 300K total and we get R&D rebate from govt when we do trials. Wouldnt be surprised if we made profit considering its 3M total but CVL is funding 2.7M of our trial costs. R&D goes to us and might literally be more than 300K we spent.
So, those are my main two peers we should catch. The difference is, the market is not 100% efficient and will take time to catch up. And also, we haven't actually completed either of those goals, we merely have them about to start. Time difference. I can assume that when we do tick our first successful trial and post quarterly of oils selling to 1000 patients, MC will once again re-rate accordingly.
QOL of Board? Ours is the best. Latham and Valentine are good but Widdows is a beast, CEO of Heinz AU and profits under him trebled iirc. And now Dr Sud Agarwal? CannVaLate Founder? All with equity and some substantial equity for Dr Sud with goals to kick to even get it. Jesus Christ, find me a better board for AU MedCann.
Punt worth taking. Your P/E type analysis is not really applicable to these medcanns, because if they were they would all trade at terrible valuations. Market's hot, sentiment's hot, for the whole sector really.
Am I wrong in anything I said? (Facts please, not subjectivity). Is this a subjective opinion? Yes. You are free to agree or disagree.
I'm not going to pursue this further, I saw the same type of post on AGH.
I look forward to re-visiting this post when trial succeeds and when oils rev come in by EOY. You are clearly not responding to my analysis and ignoring it and instead pushing a type of analysis that does not actually work with these specs, certainly not when sentiment is hot.
